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1. Introduction
The word “pemphigus” is derived from the Greek term "pemphix” meaning bubble or blister.
Pemphigus is a group of autoimmune diseases (see Table 4) characterized by intra-epithelial
blistering, resulting in superficial vesicles or bullae that easily rupture, resulting in ulceration
of mucosal and/or cutaneous sites. Although rare, pemphigus causes significant morbidity and
potential mortality for patients. The two main subtypes are pemphigus vulgaris (PV), and
pemphigus foliaceous (PF), of which PV is the most common and clinically, the most aggressive
variant, being associated with significant morbidity and mortality, composing 70% of all
reported cases of pemphigus: Less common forms and variants include paraneoplastic
pemphigus, drug induced pemphigus, and IgA pemphigus. This book chapter focuses on the
diagnosis and treatment of PV and PF.
2. Epidemiology
The estimated incidence of pemphigus is 1-16 cases per year per million people [1],[2]. PV is
the most common type of pemphigus found in the USA and Europe. In the USA, PV is 5 times
as prevalent as PF [3]. In contrast, PF is more common in certain countries such as Finland and
South Africa [4] and the endemic variety, Fogo Salvegem, affects up to 3% of the population,
in affected rural regions in Brazil, Columbia, and Tunisia [5]-[7].
3. Pathogenesis
The pathogenesis of pemphigus involves the targeting of inter-keratinocyte adhesion mole‐
cules by autoantibodies, leading to acantholysis and subsequent blister formation. There are
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four subtypes of desmoglein, which are glycoproteins that belong to a superfamily of cadherin
molecules and are essential components of desmosomal intracellular adhesive junctions [8].
The molecular target in PF is desmoglein-1, which is found predominantly in the upper layers
of the epidermis of the skin [9] [10]. Two subtypes of PV are described. In mucosal-dominant
PV, the molecular target is restricted to desmoglein-3, whereas in mucocutaneous PV, the
target is desmoglein-3 and desmoglein-1.[8] Desmoglein-3 is found in mucous membranes and
predominantly in the lower layers of the epidermis of the skin and hence explains the absence
of mucous membrane involvement in PF. Current evidence suggests that autoantibodies to
desmogleins cause the loss of this desmosome from the surface of the keratinocyte and
rearrangement of the actin cytoskeleton. This results in an unidentified cascade of signalling
events resulting in apoptotic cell death and acantholysis [11]. Autoantibodies to desmoglein-3
and desmoglein-1 are paramount in the pathogenesis of PV and PF. In PV, this is demonstrated
by the fact that passive transfer of serum IgG to desmoglein-3 into newborn mice induces
blister formation [12].
Interaction between antigen specific T cells and B cells is postulated for the production of
antibodies to desmoglein-3 and desmoglein-1. Autoantibody production has been shown, in
vitro, to be dependent on mononuclear cells [13]. Further, aberrant T cell recognition of
desmoglein-3 and desmoglein-1 is likely involved in the initiation and perpetuation of the B
cell response.
Additionally, in PV, HLA Class 2 alleles including HLA DRβ1*0402, β1*1401, β1*0503 may be
involved in the presentation of desmoglein-3 peptides to autoreactive T cells. However, similar
associations are not observed in PF [14]. Further it has been observed that autoantibodies of
the Th2-dependent IgG4 subtype are present in active disease but are not detectable in inactive
disease or healthy individuals [15]. In active disease, IgG1 and IgG4 recognises epitopes in
EC1 (amino acids 50-79, Bos 1) and EC2 (amino acids 200-29, Bos 2) of desmoglein-3. In inactive
disease, only autoantibodies of the Th1-dependent IgG1 subtype to EC1 are detectable [15].
These observations suggest that IgG4 against EC2 is the main antibody responsible for
acantholysis, but that this process may be facilitated or enhanced by IgG4 against EC1 [14].
A Th2 response predominates in PV. This suggests that Th2 cells are needed to activate B cells
to initiate antibody production [16]. Further, in PV and PF, imbalance between Th2 and Th1
cytokines in terms of the elevation of the former against the suppression of the latter is
postulated to contribute to pathogenesis [16],[17]. It is possible that Th17 and Treg pathways
may also be integral. However, the association between Th cell subsets and disease activity is
not well understood.
PV autoantibodies also bind large portions of keratinocytes outside desmosomal structures.
Autoantibodies against other keratinocyte surface antigens such as desmoglein-4, desmocol‐
lins, acetylcholine receptors, pemphaxin and α-9 acetylcholine receptors, of which some or
maybe all, may be involved in the pathogenesis of PV [8]. It is not clear whether blister
formation is a direct result of these antibodies or occurs indirectly through immune mediated
pathways which involve inflammatory cells and cytokines [14]. For instance, TNF-α is
observed to be raised in PV compared to healthy controls, and may also increase with disease
activity [16],[18].
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Genetic susceptibility by individuals that increases their risk for developing pemphigus is
suggested by studies describing associations between certain HLA polymorphisms and
subtypes of disease. For instance, HLA-DRB*0102, 0404, 1402, and 1406 have been associated
with endemic PF [5]. In 87 Italian patients, 61 with PV and 26 with PF, it was found that
pemphigus vulgaris and pemphigus foliaceus share HLA-DRB1*1401 and DQB1*0503, are
both associated with both PV and PF, whereas DRB1*0402 is only prevalent in patients with
PV [19]. In a group of 20 French patients [20] the HLA alleles DRB1*0404 and DRB1*0102 were
found to be associated with PF. It remains to be determined, whether these HLA-polymor‐
phisms are true disease susceptibility genes given their role in antigen presentation. Alterna‐
tively, they may be markers of disease susceptibility through strong linkage disequilibrium
with the causative gene. An environmental trigger may ultimately result in expression if
disease in genetically susceptible individuals as is suspected to occur in endemic PF in
Brazil[21]. Recently, it has been postulated that the inciting antigen in Brazil is a salivary
protein from a haematophagous black fly, Simulium nigrimanum [22].
Disease and Subtype(s)
(alternate terms)
Clinical Presentation Natural History/
Prognosis/
Outcome
Target
Antigens
Oral Cutaneous
Pemphigus vulgaris (PV) Common.
Usually the
first site
involved
Commonest and most aggressive form of
pemphigus: oral mucosal involvement
common and often first site of presentation
leading to extensive skin involvement.
Fatal if untreated
Good with treatment
Desmoglein 3
(Dsg 3 is more
common in oral
epithelium)
(& Desmoglein 1
(Dsg-1 & 3 are
both found in
skin))
Pemphigus vegetans Rare
(in all 3
forms of
pemphigus
vegetans)
Uncommon and less aggressive clinical
variant of PV: presents with large verrucous
confluent plaques and pustules localized to
flexural areas (axilla/groin).
Often progresses to
pemphigus vulgaris
Pemphigus vegetans
of Neumann
Often begins and ends as typical PV. Needs
more intense immune-suppression than
seen with PV, with patients troubled by
chronic relapses (and remissions).
Frequent relapses
(even with treatment)
Pemphigus vegetans
of Hallopeau
Relatively benign, usually very well localised
disease.
Prolonged remission
(with treatment)
Pemphigus foliaceus (PF) Rare All forms of PF are characterised clinically by
superficial cutaneous blisters and erosions
seen on histology as subcorneal
acantholysis.
More benign course
than PV, with
prolonged remission.
Desmoglein 1
Pemphigus
erythematosus
( “Senear-Usher
syndrome”)
Very rare condition with the combined
features of pemphigus foliaceus and SLE
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Disease and Subtype(s)
(alternate terms)
Clinical Presentation Natural History/
Prognosis/
Outcome
Target
Antigens
Endemic pemphigus
( “Brazillian
pemphigus” or
“Fogo Sevagem”
(FS))
Common
(endemic
form)
PF and FS are identical clinically,
histologically, and serologically but differ
significantly, epidemiologically, with marked
geographic clustering in Brazil, being a
diseases of people resident in/or near the
rainforests. The autoimmune response in FS
is thought to be triggered by a putative
environmental factor.
IgA pemphigus Rare
(all 3 forms
of IgA
pemphigus)
Rare, characterised by pruritic, flaccid
vesicles and/or pustules in annular pattern
with central crusting, sometimes hypopyon*
of the eye.
Pathogenesis: related to the neutrophilic
infiltrate in the epidermis rather than solely
to the binding of IgA to target epidermal
antigens.
DIF: IgA (cf IgG seen in all other forms of
pemphigus) deposits in lower epithelium or
entire epidermal cell surfaces
Recalcitrant to
treatment with
corticosteroids
Desmoglein 3
(& Desmoglein
1)
Subcorneal pustular
dermatosis
(“Sneddon-Wilkinson
disease”)
Subcorneal (beneath the stratum corneum)
blister containing neutrophils with
epidermal acanthosis and spongiosis, results
in superficial fragile blistering.
Intraepidermal
neutrophilic IgA
dermatosis
Deeper, intra-epidermal blister containing
neutrophils with epidermal acanthosis and
spongiosis, results in more marked blistering
and consequent ulceration.
Paraneoplastic pemphigus Common &
very severe
Polymorphous skin eruption, consisting of
blisters, erosions, and targetoid lesions;
severe mucous membrane involvement.
DIF: IgG deposits on entire epidermal cell
surfaces +/- granular-linear complement
auto-antibodies to rat bladder epithelium in
75% of cases.
Fatal Desmoglein 3,
Desmoplakin 1,
Desmoplakin 2,
BP 230,
evoplakin,
periplakin,
others
Familial benign
chronic pemphigus
(“Hailey-Hailey disease”)
Rare Not a true form of pemphigus, as it is not
antibody mediated.
It presents a chronic recurrent bullous and
vesicular dermatitis of intertriginous areas
that is characterized histologically by
suprabasilar acantholysis.
chronic, relapsing–
remitting course
Desmocollin 1
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Disease and Subtype(s)
(alternate terms)
Clinical Presentation Natural History/
Prognosis/
Outcome
Target
Antigens
Pathogenesis: heterozygous mutations of
the ATP2C1 gene leads to a malfunction of
the encoded protein hPMR1 - hPMR1 being
a high-affinity calcium transport ATPase
pump of the Golgi complex. A low level of
intracellular Ca2+ induces premature
keratinocyte proliferation, which leads to
dysfunctional desmosomal proteins and
thus abnormal keratinocyte adhesion.
PV = pemphigus vulgaris; PF = pemphigus foliaceous, SLE = systemic lupus erythematosus, FS = Fogo Sevagem, DIF =
direct immune-fluorescence,
cf = in contrast, BP = bullous pemphigoid, AD = autosomal dominant inheritance, Ca2+ = calcium ion
*hypopyon= sterile leukocytic exudate, seen in the anterior chamber of the eye
Table 1. Clinical and Immunohistochemical Variants of Pemphigus
4. Clinical features
4.1. Pemphigus vulgaris
Patients with PV usually present, in the initial stage, with highly painful erosions of the oral
mucosa (Figures 1, 2) [23], but other mucous membranes such as the nasal, laryngo-esophageal,
genital, anal and conjunctival mucosae can be involved. Some patients have mucosal dominant
disease whereas in others cutaneous lesions develop and manifest as flaccid blisters followed
by denuding and ulceration (Figure 3). A direct Nikolksy’s sign can be elicited where tangential
pressure on the on perilesional skin causes the epidermis to separate from the dermis. Skin
lesions have a predilection for the trunk, groins, axillae, scalp, face, and pressure points.
Secondary infection and dehydration are frequent cause of morbidity and mortality. Studies
that differentiate PV according to clinical phenotype have shown a lower mortality in patients
with predominantly mucosal PV (1–17%) compared with those with mucocutaneous PV (34–
42%)[24].
4.2. Pemphigus foliaceus
Non-endemic PF usually presents in middle age or older adults whereas endemic PF is more
common in children and young adults. FS in Tunisian affect women 4 times as often as men
[7]. In both non-endemic and endemic PF, patients usually report the eruption of blisters on
the scalp, face and upper trunk but they are fragile and some patients present instead with
multiple painful crusted erosions (Figure 4). There is no history of mucosal involvement.
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Pemphigus erythematosus is considered to be combination of PF and systemic lupus erythe‐
matosus typified by the presence of erosions in a malar distribution. Drug-associated cases
may implicate angiotensin-converting enzyme inhibitors [25], penicillamine [26] or rifampicin
[27]. There may be an intercurrent medical history of bullous pemphigoid [28], myasthenia
gravis [29] or other autoimmune diseases [30]. PF has been associated with various malignan‐
cies such as non-Hodgkin’s lymphoma [31], prostate cancer [32], and cutaneous squamous cell
cancer [33].
Figure 1. Pemphigus vulgaris with palatal ulceration and bleeding
Figure 2. Pemphigus vulgaris with desquamative gingivitis
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Figure 4. Pemphigus foliaceus characterised by exfoliative erythroderma
In both non-endemic and endemic PF, superficial flaccid vesicles and bullae may be evident
and a positive Nikolsky sign is commonly elicited. However, the fragility of these lesions result
in the formation of scaled erosions reflecting detachment of the stratum corneum from the
stratum granulosum described as a ‘corn flakes’ appearance (Figure 5). At the severe end of
the spectrum, PF can result in an exfoliative erythroderma.
Figure 3. Pemphigus vulgaris characterised by multiple ulcers over the lower back
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Figure 5. Pemphigus foliaceus with large scaly and crusted erosions over the trunk giving a ‘corn flakes’ appearance
PF causes significant morbidity as the lesions are painful and patients are prone to secondary
infection, dehydration and metabolic disturbances with fatalities reported for those cases
involving exfoliative erythroderma.
4.3. Differential diagnosis
Clinically, the differential diagnosis for mucosal lesions of PV (before the development of
cutaneous disease) includes herpes simplex virus, lichen planus, mucous membrane (cicatri‐
cial) pemphigoid: erythema multiforme, and paraneoplastic pemphigus. The differential
diagnosis for cutaneous involvement include other autoimmune blistering skin conditions,
such as pemphigus foliaceus, pemphigus vegetans, IgA pemphigus, paraneoplastic pemphi‐
gus, bullous pemphigoid, linear IgA disease, erythema multiforme, Grover’s disease, and
Hailey-Hailey disease.
The differential diagnosis of endemic and nonendemic PF includes bullous impetigo, IgA
pemphigus, pemphigus herpetiformis, drug eruptions, subcorneal pustular dermatosis, and
systemic lupus erythematosus. If lesions are localized to the face or scalp with abundant scaling
and yellow crusting, seborrheic dermatitis needs to be considered. The differential diagnosis
of exfoliative erythroderma as the manifestation of PF includes papulosquamous diseases such
as psoriasis, pityriasis rubra pilaris, and Drug Reaction with Eosinophilia and Systemic
Symptoms.
5. Diagnosis
5.1. Histopathology
In PV, biopsy of lesional skin demonstrates intraepidermal splitting that occurs suprabasally
forming an intraepidermal blister [34]. A single layer of basal keratinocytes remains attached
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to the basement membrane (tombstone pattern), which forms the floor of the blister. The roof
of the blister comprises relatively intact superficial epidermal layers with the stratum corneum
showing a basketweave pattern. Hematoxylin and eosin staining demonstrates suprabasalar
acantholysis and infiltration with predominantly neutrophils and eosinophils. A sparse
perivascular lymphocytic and eosinophilic inflammatory infiltrate is found in the upper
dermis [35] (Figure 6). In contrast, intraepidermal splitting is found subcorneally in PF with
the initial formation of vacuoles within the intercellular spaces of the granular and/or upper
spinous layers of the epidermis. [34] The vacuoles become larger and eventually lead to
subcorneal blister formation within the upper epidermis (Figure 7). Hematoxylin and eosin
staining show variable amounts of acantholytic keratinocytes, neutrophils, and fibrin within
the blisters (Figure 8). Chronic PF lesions may show evidence of papillomatosis, acanthosis,
hyperkeratosis, parakeratosis, and follicular plugging. The papillary dermis contains an
inflammatory infiltrate composed of small numbers of neutrophils, eosinophils, and lympho‐
cytes.
5.2. Direct immunofluorescence
Biopsy for direct immunofluorescence should be taken from perilesional mucosa and/orskin
[36]. Biopsy of lesional tissue is not useful as immunoreactants are rapidly degraded by
inflammatory activity [37]. To prevent the destruction of immunoreactants, specimens must
be snap frozen and stored at temperatures below -70°C or placed in special transport media
(such as Michel's medium) [36]. In direct immunofluorescence, specimens are incubated with
fluorescein isothiocyanate-labelled antibodies against immunoglobulins, complement or
fibrinogen, and examined with a fluorescent microscope [36]. In PV, direct immunofluores‐
Figure 6. Medium power view of a skin biopsy from a patient with pemphigus vulgaris showing acantholysis of the
suprabasal keratinocytes leaving a single layer of basal keratinocytes attached to the basement membrane (tomb‐
stone pattern), which forms the floor of an intraepidermal blister. The roof of the blister comprises relatively intact
superficial epidermal layers with the stratum corneum. A sparse perivascular lymphocytic and eosinophilic inflamma‐
tory infiltrate is found within the upper dermis.
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cence shows intercellular immunoglobulin G (IgG) throughout the epidermis as a result of
deposition of both anti-desmoglein-1 and -3 antibodies (Figure 9). Approximately 50% of
biopsies may display complement 3 (C3) [36]. In contrast, PF is characterized by both inter‐
cellular IgG and C3 predominantly in the upper half of the epidermis due to the increased
density of desmoglein-1 and subsequent antibody deposition in the superficial epidermis. The
diagnostic sensitivity of direct immunofluorescence in pemphigus disease is 80-95% [38].
Figure 7. Medium power view of a skin biopsy from a patient with pemphigus foliaceus showing vacuoles within the
intercellular spaces of the stratum granulosum and the upper stratum spinosum of the epidermis. The papillary dermis
contains an inflammatory infiltrate comprising neutrophils, eosinophils, and lymphocytes (hematoxylin and eosin
staining).
Figure 8. High power view of a skin biopsy from a patient with pemphigus foliaceus showing clefting with acantholy‐
sis and spongiosis (hematoxylin and eosin staining).
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Figure 9. Direct immunofluorescence of a skin biopsy from a patient with pemphigus vulgaris revealing deposition of
IgG throughout the epidermis resulting in a chicken wire appearance.
5.3. Indirect immunofluorescence
The target of pemphigus is desmoglein. Desmoglein-1 and -3 are restricted to stratified
squamous epithelium, whereas desmoglein-2 is expressed in all desmosome possessing tissues
[8]. In indirect immunofluorescence, patient serum is incubated with epithelial substrates
containing the target antigen. In pemphigus, the most frequently used substrates are monkey
esophagus, which is more sensitive for the detection of PV autoantibodies, and guinea pig
esophagus and rabbit lip mucosa, which are more sensitive for the diagnosis of PF [39]. In PV,
indirect immunofluorescence produces a characteristic chicken-wire pattern predominantly
on the lowermost epithelial layers. The result is invariably positive in active disease. PF
autoantibodies produce a chicken wire pattern in the superficial epithelial layers (Figure 10).
The positivity rate is approximately 79-90% [38]. False positives can result from patient serum
containing antibodies to cell surface antigens[39]; antibodies can be found in patients with
staphylococcal scalded skin, penicillin adverse drug reactions, toxic epidermolysis necrosis,
and burns. Importantly, patients with blood group O who have antibodies to blood groups A
and B may give low false positives on indirect immunofluorescence testing, which is avoided
by preabsorbing their sera with these blood group antigens. Indirect immunofluorescence
titers can be used as a marker of disease activity in patients[38],[40].
6. Enzyme-Linked Immunosorbent Assay (ELISA)
Indirect immunofluorescence is not reactive with all pemphigus sera and does not differentiate
between desmoglein-3 and desmoglein-1[41]. In response, ELISAs have been developed using
the recombinant ectodomains of desmoglein-1 and -3 [42]. In commercially available assays,
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these desmoglein ectodomains have been expressed in insect cells (MBL, Nagoya, Japan), or
in human HEK293 cells (Euroimmun, Lubeck, Germany) [43]. Meta-analyses suggest that
available ELISAs are highly sensitive and specific, and has a higher diagnostic accuracy than
indirect immunofluorescence [44]. The quantification of these autoantibodies is useful in
monitoring disease activity because the titre of circulating autoantibodies has been observed
to correlate with disease activity. Specifically, the level of desmoglein-1 antibodies matches
the severity of skin disease, and the level of desmoglein-3 reflects the severity of mucosal
disease [45],[46].
7. Treatment
Therapy has resulted in a drastic decline of the mortality from pemphigus rate to below 7%
[24],[47]; however, mortality still occurs, predominantly iatrogenic, caused by complications
of the immunosuppressive therapy [24],[47]. PF tends to have a relatively benign course
compared with PV. However, mortality rates of untreated endemic PF are still very high,
ranging from 40 to 60% [48],[49]. With appropriate treatment endemic PF has a mortality rate
of less than 10% [48]. The mortality of PV was 75% before the introduction of corticosteroids
in the early 1950s [47]. Studies that differentiate PV according to clinical phenotype have shown
a lower mortality in patients with predominantly mucosal PV (1–17%) compared with those
with mucocutaneous PV (34–42%)[24]. Hence, the goal of managing patients with pemphigus
is inducing and maintaining remission using those evidenced-based treatments that have a
favourable side effect profile.
Pemphigus is a rare disease and therefore it is not surprising that only a few blinded random‐
ized controlled trials have been performed to guide treatment decisions. A 2009 Cochrane
Figure 10. Indirect immunofluorescence with the serum of a patient with pemphigus foliaceus and monkey oesopha‐
gus substrate reveals deposition of specific IgG in the intercellular cement space substance of the epidermis resulting
in a chicken wire appearance. There is an increased deposition in the upper layers of the epidermis.
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review [50] assessed interventions for PV and PF and concluded that there is inadequate
information available to ascertain optimal therapy for pemphigus. They ascertained that the
quality of most studies was not high and the majority examine patients with newly diagnosed
or active disease. Another consideration in the evaluation of data is lack of generally accepted
definitions and measurements for the clinical evaluation of patients with pemphigus and the
definitions of disease control and remission. A recent consensus statement has been released
to assist with future trials enabling improved comparisons to be made [51].
As high-dose systemic corticosteroids, followed by alternate immune-suppressive agents,
serves as the mainstay of initial therapy for PV, there is the need to exclude underlying latent
infectious diseases that can be reactivated by the corticosteroids (e.g.: HIV, Hepatitis B and C,
and tuberculosis). In addition, screening for the diseases initiated or exacerbated by high-dose
‘steroids, such as hypertension, diabetes mellitus and osteoporosis is prudent.
8. Systemic corticosteroids
Systemic corticosteroids are currently the mainstay of treatment as they have a rapid onset of
action and are effective in controlling disease and improving prognosis [52]. However
significant side effects such as diabetes, osteoporosis, adrenal suppression, peptic ulceration,
weight gain, increased susceptibility to infection, mood changes, proximal myopathy,
Cushing’s syndrome, and cataracts limit their usefulness. Adjuvant treatments have therefore
been introduced as steroid sparing agents. Various corticosteroid regimens are used to treat
pemphigus, the most common of which is a gradual reduction of an oral formulation [47]. In
newly diagnosed patients, an initial daily dose of 0.5 mg/kg of prednisone/prednisolone, (or
equivalent) appears preferable to 1 mg/kg. A randomized trial compared these two regimens
in 19 patients with PV and 3 with PF followed for 5 years, with remission defined as less than
15 mg of corticosteroids per day to maintain disease control [53]. No difference was observed
in remission or the incidence of complications between the high and low dose regimens. In a
randomized trial that included only patients with newly diagnosed PV, pulsed oral dexame‐
thasone provided no additional benefit to the combination of oral prednisone and azathioprine
with remission defined as cessation of systemic treatment [54]. Furthermore, there were an
increased number of adverse events in those participants receiving pulsed dexamethasone.
However, the possible benefit of high dose pulsed intravenous corticosteroids in achieving
disease control and maintaining remission was suggested in a small case-controlled retro‐
spective study of patients with PV initially unresponsive to low dose of prednisone (less than
40 mg daily) [55] and an open study of new diagnosed PV patients [56]. There have no studies
to date examining the effects of high dose pulsed intravenous corticosteroids in PF.
Currently no optimal regimen for corticosteroid therapy has been defined for the treatment of
pemphigus despite its proven benefits. Hence in routine practice, a tailored regime is recom‐
mended. A starting dose of prednisolone 0.5 mg/kg daily is prudent that may need to be
increased, until no new blister formation is observed. Such higher doses of corticosteroids
including pulsed therapy may be warranted in newly diagnosed severe disease and recalci‐
trant disease but this remains to be substantiated in randomized studies.
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9. Adjuvant treatment of pemphigus
Immunosuppressive therapy for pemphigus includes azathioprine, mycophenolate mofetil,
methotrexate, cyclophosphamide, cyclosporin and dapsone. Adjuvant agents with immuno‐
modulatory activity that have also been used in pemphigus include calcineurin inhibitors,
epidermal derived growth factor and tetracycline antibiotics. The main role of these immu‐
nosuppressive medications is to function as a steroid-sparing agent. As they generally have a
slow mode of onset, approximately 4-6 weeks, they are used in maintenance therapy rather
than in the initiation of disease control. However, their role needs to be further elucidated as
there has been only limited number of randomized controlled trials with most of the literature
derived from case series reports.
9.1. Azathioprine
Azathioprine is a purine antimetabolite that is cleaved to 6-mercaptopurine, which in turn is
converted to additional metabolites that inhibit de novo purine synthesis. Cell proliferation is
inhibited and as a consequence a variety of lymphocyte functions are impaired. Azathioprine
is commonly used to treat pemphigus; a survey of dermatologists in 2003 showed it was the
most commonly prescribed adjuvant agent used to treat PV [57]. It has even been used as
monotherapy in mild cases [58]. In a recent randomized trial conducted by Chams-Davatchi
et al, 120 new patients with PV were treated for over one year with one of four regimens. These
regimes were prednisolone alone, prednisolone plus azathioprine, prednisolone plus intrave‐
nous cyclophosphamide and prednisolone plus mycophenolate mofetil [59]. Azathioprine
reduced the cumulative dose of prednisolone compared with prednisolone alone however
remission rates were similar. Side effects were similar between the two groups. Thus in this
trial, which included only patients with PV, azathioprine reduced the cumulative corticoste‐
roid dose but not the rate of remission. More recently, a non-randomized study compared high
dose oral prednisone daily (1.5 mg/kg/daily) versus low dose oral prednisone (40 mg on
alternate days) plus azathioprine (100 mg/daily) in 36 patients with oral PV [60]. Both treat‐
ments resulted in high rates of clinical remission; the monotherapy group showed a reduced
mean time to remission but this group was associated with an increased rate of treatment-
associated adverse events Other non-randomized trials using azathioprine are have generally
shown favourable outcomes in PV [61],[62].
9.2. Mycophenolate mofetil
Mycophenolate mofetil is a prodrug and its active drug, mycophenolic acid, inhibits inosine
monophosphate dehydrogenase, an important enzyme in guanine nucleotide synthesis.
Lymphocytes are highly dependent on this pathway and are selectively inhibited by myco‐
phenolate mofetil [63]. In the randomized trial by Chams-Davatchi et al, no difference in
remission was observed for mycophenolate mofetil when compared to prednisolone alone
[59]. In this same study no difference in remission was demonstrated between azathioprine
and mycophenolate mofetil. The steroid sparing effect of mycophenolate mofetil was inferior
to azathioprine. Beissert et al. compared oral methylprednisolone plus azathioprine with
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mycophenolate mofetil in 33 patients with PV and 7 patients with PF [64]. The primary outcome
was complete healing of all lesions. This study concluded that mycophenolate mofetil and
azathioprine demonstrated similar efficacy. Safety profiles were similar as was corticosteroid-
sparing effects. There were less severe side effects observed in the mycophenolate group but
this was not statistically significant. Many non-randomized trials have supported the use of
mycophenolate mofetil in the treatment of pemphigus [65]-[69]. The majority of patients in
these trials had PV. Mycophenolate mofetil is generally well tolerated; lymphopenia, gastro‐
intestinal symptoms and infections are the most common side effects. Currently it is a relatively
expensive medication, often precluding its off-label use. The drug is usually commenced at
dose of 1 g per day in adult patients, and if required, increased in 500-mg increments up to
doses of 2-3 g per day [70].
9.3. Cyclophosphamide
Cyclophosphamide is an alkylating agent that disturbs DNA synthesis and cell division.
Cyclophosphamide interferes with DNA integrity and function inducing cell death in rapidly
proliferating tissues including lymphocytes. This provides the basis for their therapeutic and
toxic properties. Several randomized trials have assessed cyclophosphamide in treatment of
pemphigus. Chrysomallis et al. used oral cyclophosphamide in patients with PV whose disease
was limited to oral involvement [71]. Twenty-eight patients were divided into 3 groups and
given corticosteroids alone, corticosteroids with cyclophosphamide or cyclosporine. No
difference in remission was seen when cyclophosphamide was compared with corticosteroids
alone, and at 5 years, all patients had their disease controlled with a low dose corticosteroid
regimen. The more recent study by Chams-Davatchi et al. described above and comprising
entirely of patients with PV concluded that there was no difference in remission rates following
pulsed intravenous cyclophosphamide therapy [59]. A randomized control trial that included
6 patients with PF as well as 16 with PV compared pulsed cyclophosphamide with dexame‐
thasone and daily cyclophosphamide with methylprednisolone plus azathioprine [72]. No
difference in disease control was observed for the cyclophosphamide group compared to the
azathioprine group after 2 years. Several non-randomized case series have utilized pulse
cyclophosphamide with variable outcomes [73]-[75].
Given the lack of superiority of cyclophosphamide over other regimes in randomized trials
and its well-described serious side effect profile, the authors recommend that its use be
restricted for the treatment of severe or refractory cases of PF, where alternative agents such
as rituximab or IVIg are not available.
9.4. Cyclosporin
Cyclosporin is a calcineurin inhibitor that prevents dephosphorylation of nuclear factor of
activated T cells (NFAT) preventing its translocation into nucleus and as a consequence the T
cells fail to respond to specific antigenic stimulation. Cyclosporin also increases expression of
TGF- beta, a potent inhibitor of IL-2–stimulated T-cell proliferation. A randomized trial
compared oral methylprednisolone alone with oral methylprednisolone plus cyclosporin in
33 newly diagnosed patients, 29 with PV and 4 with PF [76]. The patients were followed for
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4-6 years and the investigators concluded that the combination regimen of corticosteroids and
cyclosporin provided no additional benefit over corticosteroids alone. Side effects, including
hypertrichosis, hypertension and renal dysfunction, were more common in the cyclosporin
group. The randomized controlled study by Chrysomallis et al. in newly diagnosed PV limited
to oral involvement found no difference in remission or relapse rates between the cyclophos‐
phamide and cyclosporine (5 mg/kg) groups [71]. Again, adverse events were more common
in the cyclosporin group and included hypertrichosis and renal impairment. A case series
reported successful the successful treatment of 6 patients with recalcitrant PV [77].
The randomized trials have not supported the use of cyclosporine at a dose of 5 mg/kg for the
treatment of new onset pemphigus and side effects are relatively common. Further random‐
ized controlled trials are required to determine its benefit in recalcitrant disease.
9.5. Dapsone
Dapsone has anti-inflammatory and antimicrobial actions. Its immunomodulatory action is
incompletely understood but several actions have been described including prevention of the
respiratory burst from myeloperoxidase, suppression of neutrophil migration by blocking
integrin-mediated adherence, inhibition of adherence of antibodies to neutrophils, and
reduction of eicosanoid release. Most studies utilising dapsone have been performed in
patients with PV. A randomized controlled trial performed in 19 patients, all with PV,
compared dapsone with placebo [78]. Patients were in the maintenance phase after glucocor‐
ticoids and/or cytotoxic agents (azathioprine, mycophenolate or methotrexate) were used to
achieve remission. Doses of dapsone were increased to 150 mg per day and then to a further
200 mg per day if tolerated. The trial was performed over 1 year, and the main outcome
measured was reduction of prednisolone to doses of 7.5mg/day or less. Five of the 9 patients
in the placebo group achieved the main outcome compared with 3 out of 10 in the placebo
group. The difference was not statistically significant although there was a trend favouring
dapsone as a steroid sparing agent. A retrospective study in 9 patients with PV suggested that
dapsone reduced steroid dependence in these patients [79]. Another study reported improve‐
ment in 5 of 9 cases of superficial pemphigus treated with dapsone [80]. A recent meta-analysis
comprising 55 patients with pemphigus revealed that 32 patients with PV and 14 patients with
PF responded to dapsone [81].
The side effects of dapsone observed in these studies include methaemoglobinaemia, haemol‐
ysis and agranulocytosis. [81],[82] Patients should be tested for glucose-6-phosphate dehy‐
drogenase deficiency prior to commencing this agent. Dapsone at best may have a role as a
steroid sparing agent in the maintaining remission in pemphigus but cannot be recommended
in treatment of acute disease.
9.6. Methotrexate
The antimetabolite methotrexate is a folic acid analogue that competitively inhibits dihydro‐
folate reductase and has multiple immunosuppressive actions including suppressing lym‐
phocytes in the skin [83],[84]. A small number of non-randomized trials have investigated the
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role of methotrexate in treatment of pemphigus. The most recent study [83] treated 9 patients
with chronic active PV, who were unable to successfully wean their prednisolone dose. They
were treated with a mean dose of 12.5 mg per week of methotrexate. Prednisolone was
discontinued in 6 of the 9 patients within 6 months of commencing methotrexate. There were
minimal adverse effects reported in the study. A recent review of the English literature
revealed that 111 (82%) of 136 pemphigus patients responded to methotrexate [85]. However,
meaningful conclusions are limited by the lack of randomized trials, varying doses and
schedules of treatment, and insufficient information on clinical progress including the lack of
consistency of the length of follow up.
Thus methotrexate may be useful as a steroid sparing agent but further trials are required
before recommending methotrexate as an initial steroid-sparing agent.
Medication Dose Contra-indications
Pre-Therapeutic
Investigations
Monitoring Adverse Reactions
Corticosteroids
(“steroids”)
prednisolone:
(1) ½-1 mg per kg/
bodyweight of the
patient for 4 days
(or longer in pemphigus)
with rapid taper until
clinical remission occurs
(2) < 7.5 mg/daily
∙ Active infectious
diseases: Tb, HIV, HBV,
HCV
∙ Tb, HIV, HBV, HCV Systemic:
∙ hypertension,
psychosis, diabetes
mellitus, weight gain,
cataracts
hypertension, psychosis,
diabetes mellitus,
weight gain, cataracts
Oral Mucosa:
candidiasis,
mucosal atrophy
Oral Mucosa:
∙ candidiasis, mucosal
atrophy
Calcineurin-
Inhibitors:
pimecrolimus
(Elidel®)
Topical Application
Only: A causal relationship has not been established with malignancy. Skin cancer
and lymphoma have been reported in patients treated with topical
calcineurin inhibitors, including pimecrolimus 1% cream.
irritation, pruritis and
erythema on application
thin layer to affected
mucosa twice daily
Lysosomotropic
Amines:
hydroxyl-
chloroquine
(Plaquenil®)
200-400 mg
(once daily)
∙ pre-existing
retinopathy
∙ psoriasis
∙ porphyria
∙ G6PD deficiency
∙ baseline visual acuity
testing (for macular
degeneration) by an
Ophthalmologist
∙ annual baseline visual
acuity testing
∙ FBC and LFT's weekly
for first 4 weeks;
thereafter, only if
indicated
UV (sun) light–initiated
lichenoid cutaneous
reactions
∙ FBC; G6DP levels; LFT’s
Note: slow onset of
action of up to 3 months
azathioprine
(Imuran®)
1.0-2.0 mg
per kg bodyweight/daily
(once daily)
∙ recent use of live
vaccines
∙ pregnancy (Category
D) (including partner of
male patient)
∙ concomitant
allopurinol
∙ thiopurine methyl-
transferase (TPMT) assay
(determines risk of bone
marrow aplasia)
∙ FBC weekly for first 8
weeks; thereafter
monthly
severe adverse reaction
with xanthine oxidase
inhibitors of which the
most potent is
allopurinol (Progout®
Zyloprim®)
∙ FBC; LFT’s; E/U/C
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mycophenolate
(CellCept®,
Myfortic®)
max 2 g/day
(once daily or
divided dose)
∙ pregnancy (Category
D)
∙ HIV, HBV, HCV ∙ FBC and LFT’s weekly
for first 4 weeks;
thereafter, only if
indicated
malignancy risk eg skin
cancer, lymphoma;
infection; progressive
multifocal leuco-
encephalopathy; bone
marrow depression
dapsone
(Dapsone®)
maintenance dose:
50-100 mg daily
(≥ 300 mg daily
∙ FBC, G6DP levels, LFT’s
∙ HIV, HBV, HCV
∙ FBC, LFT’s weekly for
the first month, monthly
for six months and semi-
annually thereafter
dose related haemolysis,
especially in G6DP
deficient patients;
agranulocytosis; toxic
hepatitis and cholestatic
jaundice
methotrexate
(Methoblastin®)
10 to 25 mg/ ∙ pregnancy (Category
D)
∙ liver/renal
impairment
∙ HIV, HBV, HCV
∙ immune-deficiency;
∙ concomitant
retinoinds
FBC, LFT’s, E/U/C
HIV, HBV, HCV
∙ FBC weekly for first 8
weeks, thereafter
monthly
hepato/ nephrotoxicity;
ulcerative stomatitis;
bone marrow
depression; immune-
suppression
WEEKLY ONLY
until adequate response
is achieved
Rituximab
(Mabthera®)
375 mg/m2 (body
surface area) once
weekly
∙ Murine(mouse)
protein hypersensitivity
∙ Tb, HIV, HBV, HCV ∙ infection progressive multifocal
leucoencephalopathy
(PML)
for 4 weeks
or 2x 1.0g -500 mg ivi
infusions over two
weeks
(A)
Medication Actions
corticosteroids
(“ ‘steroids)
Profound, generalised inhibitory effects on inflammatory processes and cells achieved by the control of protein synthesis by
reacting with certain corticosteroid responsive genes of sensitive cells in many tissues:
⇩ production of acute inflammatory mediators, especially eicosonoids, postaglndins and leukotrienes. (corticosteroids increase
the production of a polypeptide – lipocortin, that in turn inhibits phospholipase A2 the enzyme responsible for the mobilising
arachniodonic acid from cell membranes)
⇩ production and numbers of circulating immune-competent cells: e.g.: neutrophils, macrophages, T and B lymphocytes
⇩ Complement activation
⇩ activity of macrophages and fibroblasts involved in the chronic stages of inflammation – leading to decreased inflammation
and healing
cyclosporine
tacrolimus
Calcineurin inhibitors:
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pimecrolimus ∙binds to the cytosolic protein cyclophilin of T-lymphocytes and the complex of cyclosporin (or other calcineurin-inhibitor) and
cyclophilin inhibits calcineurin, which normally induces the transcription of interleukin-2.
⇩ lymphokine production and interleukin release (further reducing the function of effector T-cells)
hydroxyl-
chloroquine
(Plaquenil®)
Lipophilic weak base that passes easily through plasma membranes to accumulate in acidic vesicles, such as the lysosomes of the
inflammatory cells and acts by:
⇩ antigen presentation by the antigen-presenting cells (APC’s)
⇩ cytokine production (e.g.: Tumour Necrosis Factor-alpha (TNF-α), Interleukin-6 (IL-6), Interferon-gamma (IFN-γ))
⇩ stimulation of the toll-like receptors
∙ prostaglandin antagonist
azathioprine
(Imuran®)
Azathioprine is an imidazole derivative of 6-mercaptopurine (6-MP) into which is rapidly broken down (in vivo).
∙ 6-MP readily crosses cell membranes and is converted intracellularly into a number of purine thioanalogues, including the main
active nucleotide: thioinosinic acid.
∙ thioinosinic acid inhibits many pathways in nucleic acid biosynthesis causing damage to deoxyribonucleic acid (DNA), through
incorporation of this “false” purine thio-analogue.
∙ this action is restricted to the cells involved in determination and amplification of immune response; the B and T lymphocytes as
they are unable to source alternate or extrinsic nucleotides being entirely dependent for their proliferation on de novo synthesis
of purines, whereas other cell types can utilise salvage pathways.
mycophenolate
(CellCept®,
Myfortic®)
Mycophenolic acid (MPA) is a potent, selective, uncompetitive and reversible inhibitor of inosine monophosphate dehydrogenase
(IMPDH) which inhibits the de novo pathway of guanosine nucleotide synthesis but without incorporation into the cell’s DNA:
∙ MPA has more potent cytostatic effects on T and B lymphocytes than on other cells because these cells are entirely dependent
for their proliferation on their de novo synthesis of purines, whereas other cell types can utilise salvage pathways
∙ depletion of guanosine nucleotides also leads to the inhibition of glycosylation of the adhesion molecules on lymphocytes
further interfering in their immune functions
dapsone
(Dapsone®)
Dapsone is effective in dermatoses with abnormal neutrophil accumulation
∙ Dapsone interferes in chemotactic-mediated migration of neutrophils and neutrophil function by: (1) inactivating the function
of the G-protein (Gi type) that initiates the signal transduction cascade common to chemotactic stimuli; (2) the cytokine mediated
adherence of neutrophils to the vascular endothelial cells; and (3) inhibits neutrophil MPO-mediated iodination and cytotoxicity
and eosinophil peroxidise, thereby, dapsone suppresses neutrophil recruitment and protects cells from neutrophil- and
eosinophil-mediated injury by directly inhibiting the generation of toxic, oxygen-derived radicals.
∙ in antibody mediated diseases, dapsone appears to interfere in the adherence of neutrophils to the auto-antigenic antibodies
(IgA and IgG) bound to the various target sites in the basement membrane zone, so protecting the epithelial cells from
neutrophil-derived cytolytic agents
⇩ release of prostaglandins and leukotrienes and so blocks their inflammatory effects
methotrexate
(Methoblastin®)
Antimetabolite cytotoxin. Methotrexate (MTX) competitively inhibits the enzyme dihydrofolate reductase and so prevents the
regeneration of intermediates (such as tetrahydrofolate) essential for the synthesis of purines and thymidylate so preventing DNA
synthesis:
∙ actively proliferating tissues such as the bone marrow stem cells, dermal epithelium, and lymphocytes (as well as the oral
mucosal cells) are in general more sensitive to the effects of MTX
∙ MTX has more potent cytostatic effects on T and B lymphocytes than on other cells because these cells are entirely dependent
for their proliferation on their de novo synthesis of purines, whereas other cell types can utilise salvage pathways
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Rituximab
(Mabthera®)
Rituximab is a genetically engineered chimeric murine/human monoclonal antibody that binds specifically to the antigen CD20, a
transmembrane molecule located on pre-B and mature B-lymphocytes, only. This non-glycosylated phosphoprotein is found on
both normal (and malignant B cells), but not on haemopoietic stem cells, pro-B cells, normal plasma cells or other normal tissues:
∙ inhibits CD20 which regulates the early steps in the activation process for B-cell cycle initiation and differentiation
∙ the depletion of circulating autoreactive B cells (for up to 12 months) and , presumably specific downregulation of dsg3-specific
CD4(+ve) T-lymphocytes and the associated release of proinflammatory cytokines
mayre-establish immune homeostasis and tolerance
(B)
A: Tb = tuberculosis, HIV = human immune-deficiency virus, HBV = hepatitis B virus, HCV = hepatitis C virus, G6DP = glucose-6-phosphate dehydrogen‐
ase, FBC – full blood count, LFT’s = liver function tests, UV = ultraviolet light, E/U/C = electrolytes/urea/creatinine
B: ⇩ = decreased or reduced
Table 2. (A) Therapeutic Agents Useful in the treatment of Pemphigus, (B) Therapeutic Agents Useful in Treating of
Pemphigus
9.7. Gold
Auad [86] performed a blinded placebo-controlled randomized trial on the utility of auranofin
in 30 patients with PF. Nearly one third of the patients withdrew from the active treatment
arm due to side effects. In the placebo group, a reduction in the mean corticosteroid steroid
dose was evident. Other case series comprising patients with PV and/or PF have described
similar findings [87]-[89]. The most recent study published showed that 62% of patients with
PV achieved remission or halve their dose of prednisone during a period of 10 years of
intramuscular gold therapy [90]. However, the mean time to halve the dose of prednisone was
3 months and 42% developed side effects blood dyscrasia, proteinuria and nephrotic syn‐
drome, cutaneous reactions and dizziness. These adverse effects in addition to the relatively
long time to take effect as a steroid-sparing agent preclude its use in favour of other steroid-
sparing agents in the treatment of treatment of pemphigus.
9.8. Tetracycline antibiotics and nicotinamide
Tetracycline antibiotics with and without nicotinamide have been combined with other
adjuvant agents as treatment for pemphigus. Several small non-randomized trials have shown
varying results [91]-[93]. Minocycline given at a dose of 100 mg per day allowed the reduction
of prednisolone in 6 out of 10 patients with pemphigus [91]. Tetracycline at a dose of 2 g per
day for 1 month reducing to 1 g per day for 4 weeks enabled more rapid tapering of cortico‐
steroids in 13 patients with PV [93]. However the study by Alspoy found that a combination
of tetracycline (2 g/d) and nicotinamide (1.5 g/d) for 2 months was not an effective alternative
to the classic forms of therapy in 14 patients with pemphigus [92]. Further trials are needed
before recommending these agents.
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9.9. Topical agents
9.9.1. Epidermal growth factor
A double-blind randomized controlled study investigated the use of epidermal growth factor
(EGF) on skin lesions of 20 patients with PV [94]. Topical epidermal growth factor 10 ug/g in
0.1% silver sulfadiazine cream was applied to skin lesions daily until lesions had healed and
compared to the effect of applying 0.1% silver sulfadiazine (SSD) cream alone. Topical EGF
appeared to hasten lesion healing by a median of 6 days compared to SSD.
9.9.2. Topical corticosteroids (Clobetasol)
A small study comprised of 4 patients with mild PF and 3 with mild PV were treated with the
very potent topical corticosteroid, Clobetasol propionate 0.05%, as a sole agent [95]. The cream
was applied to mucosal lesions and involved skin twice a day for at least 15 days, then
progressively tapered. Control of disease was defined as healing of lesions was obtained, with
a 75% decrease in the number of new lesions per week without the addition of systemic
treatment. Disease control was achieved in all 7 patients, with cutaneous remission attained
in 15 days, although mucosal regression occurring more slowly. In 4 patients, remission was
maintained with topical corticosteroid alone for a mean 19-month follow up. In 3 patients,
relapse occurred after 2-11 months, requiring systemic treatment. Another study is in progress
comparing the effect of Clobetosol with placebo in pemphigus vulgaris.
9.9.3. Topical calcineurin inhibitors
Tacrolimus and Pimecrolimus are non-steroidal immunomodulatory macrobactams that
inhibit the enzyme, calcineurin, impairing the production and IL-2 and subsequent T-cell
activation and proliferation [96]. A small number of case reports and case series suggest a
useful role for Tacrolimus in mild PV and PF but further randomized controlled trials are
required to clarify its role in this setting [97]-[99]. A recent double blind study of 11 patients
with PV refractory to azathioprine and corticosteroids showed a marked response to pime‐
crolimus 1% by day 15 when compared to placebo using the epithelialization index [100].
10. Novel therapies and strategies
10.1. Biological agents
10.1.1. Rituximab
Rituximab is a chimeric (human/murine) monoclonal antibody directed against CD20, a cell
surface molecule specific to B cells. Although it was initially approved for use in B-cell non-
Hodgkin’s lymphoma, a growing number of reports have described the efficacy of rituximab
for B-cell depletion in the treatment of autoimmune diseases [101]. The mode of action of
rituximab in autoimmune diseases includes the removal of precursors of autoantibody-
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producing plasma cells, and impairment of autoantigen presentation to CD4 cells [102]. In PV,
Eming et al, show that rituximab not also causes marked reduction of anti-desmoglein 3
antibodies but also depletion of desmoglein-specific CD4 cells. In contrast, tetanus toxoid-
specific CD4 cells were not affected nor were the overall number of CD4 cells [103]. Tetaus
toxoid has been used in as an antigen in the assessment of memory CD4 cell responses [104].
Eming et al, speculate that this specific effect of rituximab on autoreactive rather than patho‐
gen-specific T cells is that the latter do not require CD20 B cells as antigen-presenting cells. A
number of case reports and series have demonstrated the benefit on the use of rituximab in
over 40 patients with either PV or PF [40],[105]-[115]. The largest case series to date comprising
42 patients, 37 with PV and 5 with PF, utilized the rheumatoid arthritis protocol where two 1g
infusions of rituximab are administered 15 days apart [116]. Patients were followed for up to
5 years and 36 of the 42 patients achieved a complete response and were able to cease corti‐
costeroids within 6 months from induction therapy. Twenty patients experienced relapses with
the time to relapse ranging from 8 to 64 months. Relapses were treated with rituximab (500
mg) without corticosteroids resulting in a new complete response. Importantly, no serious
adverse events were observed.
The largest case series to date using the lymphoma protocol where rituximab is administered
weekly (375 mg/m2) for 4 weeks induced remission in 12 of 14 patients with PV and 6 of 7
patients with PF within 3 months [117]. These patients had previously not responded to first-
line immunosuppressive agents or had contraindications to corticosteroid therapy. The
treatment was generally well tolerated; however, two cases were complicated by severe
infection, one resulting in death. Similarly, Canchini et al, showed that the administration of
rituximab, 375 mg/m2 once weekly for 4 weeks, induced remission in all 10 patients with PV
and both patients with PF [118]. Another study comprising 11 patients with refractory PV,
evaluated the effect of combination therapy consisting of 10 infusions of rituximab (375
mg/m2) and 6 infusions of intravenous immunoglobulin (IVIg) (2 g/kg body weight) admin‐
istered over a 6-month period [119]. Remission was induced in 9 patients for a period of 22 to
37 months following treatment and there were no reports of serious adverse events.
More recently, Kasperkiewicz et al reported use of rituximab in combination with immunoad‐
sorption, pulsed dexamethasone and azathioprine or mycophenolate mofetil in 23 patients.
[120] IA was performed at initially 3- and later 4-week intervals until lesions healed by 90%;
1 g rituximab was given at weeks 1 and 3, and intravenous dexamethasone pulses were
administered at first every 3 weeks and then at increasing intervals in addition to daily
azathioprine or mycophenolate mofetil. All patients demonstrated clinical improvement
within the first few weeks of therapy accompanies by a concomitant rapid fall in anti-desmo‐
glein antibody levels. However, two patients had non -atal severe adverse events; one
developed Staphylococcus aureus sepsis from a central intravenous line followed by spinal
haemorrhage and transient paraplegia, and another developed extensive herpes simplex
infection
The high frequency of treatment failure with corticosteroids and first line immunosuppressive
therapies has raised the issue of whether rituximab should be implemented earlier in the
treatment of PV. Horvath et al conducted a study comprising 15 patients (12 with PV, 3 with
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PF) who were treated with two infusions of rituximab (500 mg each) at an interval of 2 weeks
[121]. All 15 patients responded to therapy. Eight patients achieved complete remission in a
median period of 5 weeks. Seven patients achieved partial remission in a median period of 34
5 weeks. Relapses (40%) were seen between 53 and 103 weeks after start of therapy.
In the majority of these studies, abrogation of peripheral B cells and concomitant reduction in
the level of circulating antipemphigus autoantibodies for 6 to 12 months occurs with only two
to four infusions of rituximab. Interestingly, clinical remission in both PV and PF is often
sustained beyond B cell recovery. The reason as provided Mouquet et al, is that the phenotype
of restored B cells following rituximab treatment is that of a naïve B cell with a diverse
repertoire rather than a primed autoreactive B cell [122].
Accumulation of the data from case reports and series reveals that 16% of patients with PV
developed the serious complications of bacterial sepsis, fatal Pneumocystis jirovecii pneumonia,
persistent hypogammaglobulinemia or pulmonary embolism [123]. Concerns have also been
raised regarding the role of rituximab and other biological agents used in patients with other
immune-mediated diseases such as rheumatoid arthritis developing Progressive Multifocal
Leukoencephalopathy (PML) [124]. PML is an inevitably fatal demyelinating disease of the
central nervous system, that occurs almost exclusively in immunosuppressed individuals due
to reactivation of the polyomavirus JC (JCV) [125]. This is in contrast to rarity of adverse events
observe in patients treated for non-Hodgkin’s lymphoma [126]. Although, the question has
been raised of the use of rituximab as a first line agent due to the impressive rates of remission
[127], the incidence of serious side effects may at present preclude its role in initial therapy.
Ongoing surveillance of patients treated with rituximab for pemphigus and other autoimmune
diseases is required to monitor for long-term complications.
There is enough evidence to suggest that rituximab should be the therapy of choice for patients
with pemphigus who have refractory disease or contraindications to first-line immunosup‐
pressive therapy although randomized controlled trials have not been performed and as such,
there is no uniform protocol on its administration. The value of adjunctive therapies such as
IVIg and IA in patients treated with rituximab for pemphigus needs to be also further
elucidated. However, one of the most important questions to address is whether it is cost
effective and safe to administer rituximab for PV and severe PF as a first line agent.
10.1.2. TNF-antagonists
Studies have demonstrated that TNF released by keratinocytes plays a role in acantholysis in
PV. Human keratinocytes pretreated with anti-TNF antibodies, are resistant to the acantholytic
effect of anti-desmoglein 3 antibodies [128],[129]. Furthermore, TNF-deficient mice are more
susceptible to blister formation after injection with anti-desmoglein 3 antibodies [128]. The role
of TNF in PF has not been as extensively studied. Etanercept [130]-[133], infliximab [134],[135],
and adalimumab [136], have all demonstrated benefit in a small number of patients with
refractory PV. Randomized controlled trials of infliximab and etanercept in refractory PV are
currently in progress. However, the effect of these agents in refractory PF has not been reported
to date.
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10.2. Intravenous immunoglobulin
IVIg is a fractionated and purified blood product derived from the pooled plasma of up to 15,
000 healthy donors. Hence it has a high concentration of IgG with a broad range of specificities
against various antigens [137]. The mode of action of IVIg in autoimmune disease has not been
clearly defined but is probably multifactorial and includes provision of anti-idiotypic anti‐
bodies, modulation of expression and function of Fc receptors thereby neutralizing the effect
of pathogenic antibodies, blocking of complement activation, reduced secretion of pro-
inflammatory cytokines through modulation of dendritic, T and B-cell activation [138],[139].
IVIg upregulates endogenous caspase inhibitors protecting keratinocytes from proapoptotic
molecules and thereby inhibits acantholysis [140]. In PV, IVIg causes a selective and rapid
decline in serum levels of pathogenic antibodies, specifically IgG1 and IgG4 anti-desmoglein-1
and anti-desmoglein-3 antibodies without affecting total serum IgG levels [141],[142]. A
reduction in anti-desmoglein-1 antibodies also occurs in PF [143]. FcRn receptors, which
normally function to protect serum IgG from degredation, are saturated following IVIg
resulting in catabolism of all IgG molecules including autoreactive antibodies [144]. However,
pathogenic autoantibodies are selectively reduced because catabolized normal antibodies are
replaced by those present in the IVIg preparation [141].
Three case series and 1 retrospective analysis comprising 54 patients with refractory PV
documented the induction of clinical remission following IVIg in all but 2 patients [145]-[148].
Two case series involving a total of 15 patients with refractory PF all responded to IVIg [149],
[150]. One of these studies featuring 7 patients revealed a prolonged mean remission time of
18.6 months following discontinuation of IVIg [150]. Two retrospective analyses that included
17 patients with refractory PV and 2 patients with refractory PF, however, demonstrated a
much less favourable response with the majority of patients harbouring active disease
following IVIg [151],[152]. Recently, a double blind randomized study investigated the effect
of a 5 day course of IVIg at varying doses (400, 200 or 0 mg/kg/day) in 40 patients with PV and
21 patients with PF resistant to doses of steroids greater that 20 mg daily [153]. The study did
not specify whether these patients had previously been treated with or were currently
receiving corticosteroid-sparing immunosuppressive agents. The patients were maintained on
their study entry dose of corticosteroids for the duration of the trial. The primary end point
was the time to escape from the protocol, which was defined as the length of period that the
patient remained on the protocol, without any additional treatment. Patients that showed no
improvement after 2 weeks or developed fresh lesions necessitating an increase in corticoste‐
roids or additional immunosuppression were considered as having escaped from the protocol.
The study demonstrated a significantly longer time to escape the protocol, and a lower disease
activity index accompanied by a fall in anti-desmoglein antibody levels in the 400 mg/kg/day
group at days 43 and 85 for both PV and PF patients. There were no significant differences in
the side effects observed between the groups. Adverse events that were reported in a minority
of patients included fever, headache, palpitations, hypertension, gastrointestinal bleeding,
increased creatinine, abnormal liver function tests, and anemia. One patient in the 200 mg/kg/
day died as a result of liver failure from exacerbation of pre-existing chronic hepatitis C. Hence,
this study does provide useful evidence for the efficacy of IVIg in both PV and PF. Cessation
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of IVIg may result in new synthesis of autoantibodies exceeding that initially present [154] and
this rebound in antibody levels may minimized by concurrent cytotoxic therapy.
Comparative trials in refractory disease with other modalities such as biological agents and
extracorporeal treatments still need to be performed. The considerable expense of IVIg
warrants clarification of the optimal dose, frequency and duration of therapy. Further studies
are required to determine whether IVIg can be ceased once remission is achieved, and the
patient maintained on conventional first line immunosuppressive agents to minimize rebound
synthesis of pathogenic antibodies.
10.3. Extracorporeal treatments
10.3.1. Plasmapheresis
Plasmapheresis  results  in  the  potential  removal  of  pathogenic  antibodies  from  the  pa‐
tient’s plasma. Forty patients with pemphigus were recruited in a multicentre study and
randomized  to  receive  prednisone  alone  or  prednisone  and  plasma  exchange,  which
consisted of 10 treatments over 4 weeks [155]. No adjuvant immunosupressive therapy was
used  for  any  of  the  patients.  No  difference  was  observed  between  the  2  groups.  Four
patients in each group did not achieve disease control. Four patients in the plasmaphere‐
sis group died from either sepsis or thromboembolism. The lack of response is surprising
as Nagasaka et  al,  demonstrated in 15 patients with PV and 1 patient with PF that one
centrifugal  plasmapheresis  treatment eliminates 15% of  the IgG autoantibodies as  meas‐
ured in the effluents and this is reflected in serum measurements performed one day later
[156].  Numerous case series have demonstrated benefit  in severe or recalcitrant pemphi‐
gus when plasmapheresis is combined not only with corticosteroids but other immunosup‐
pressive agents as well [157]-[161]. Many of these patients experienced side effects including
thrombocytopenia,  hypocalcemia,  urticaria,  fever,  hypotension,  acute  hepatitis,  nausea,
dizziness and leg cramps. The beneficial response observed in these case series studies in
contrast  to  the  randomized  controlled  study  of  Guillaume  et  al,  may  therefore  be  ex‐
plained  by  the  concurrent  use  of  immunosuppressive  agents  in  order  to  prevent  the
rebound  production  of  autoantibodies.  Hence  further  randomized  control  studies  are
needed to clarify the value of plasmapheresis combined with immunosuppressive therapy.
10.3.2. Immunoadsorption
Immunoadsorption (IA) is an extracorporeal treatment for the selective removal of antibodies
and circulating immune complexes from plasma. This differs from plasmapheresis, which
nonspecifically removes plasma proteins including clotting factors, hormones and albumin,
thus requiring substitution of fresh frozen plasma or albumin. The Food and Drug Adminis‐
tration approved IA for the treatment of rheumatoid arthritis, idiopathic thrombocytopenic
purpure and hemophilia with inhibitors. It has also been used off label for the treatment of
various autoimmune mediated conditions including dilated cardiomyopathy, systemic lupus
erythematosus, myasthenia gravis and autoimmune bullous disorders [162].
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Initially, 4 case series and 2 case reports totalling 31 patients with PV and 5 patients with PF
reported efficacy for IA in combination with immunosuppressive therapies in the treatment
of recalcitrant disease [163]-[167]. The treatment schedule generally consisted of 3 initial cycles
on consecutive days, a fourth cycle on day 8, followed by 19 cycles in incrementally prolonged
intervals of 1 to 4 weeks. However, relapses are common once IA is discontinued and concur‐
rent immunosuppressive therapy tapered [167]. More recently, a small case series comprising
7 patients with refractory PV demonstrated that 23 cycles of IA administered 40 weeks, as
described above, in combination with rituximab (375 mg/m2 weekly for 4 weeks) and con‐
comitant conventional therapy resulted in complete remission in 3 patients for a period of
between 13 and 30 months with minimal or no maintenance immunosupresion [168]. One
patient attained partial remission but required significantly less dose of corticosteroids than
prior to IA and rituximab. The remaining 3 patients relapsed following the completion of
treatment. Two of these patients achieved remission when IVIg (2 g/kg body weight every 4
weeks) was administered and the other only partially responded to IVIg. A retrospective study
on refractory PV compared the efficacy of IA in 6 patients with rituximab in 5 patients and
showed remission in all patients at 6 months [169]. This remission was sustained in all patients
who had received rituximab compared to half of those that received IA. Randomized trials are
required to compare the efficacy of rituximab or IVIg with IA and determine any additional
benefit from a combination of these modalities.
The treatment is generally well tolerated. Rare adverse events that have been reported include
catheter related sepsis, Pneumocystis jerovecii pneumonia, mild hypotension, bradycardia and
in relation to anticoagulant use, hypocalcemia and paraesthesia. The trials by Schmidt et al,
and Shiminovich et al, showed that the combination of IA and immunosuppression resulted
in anemia in 30% of patients [164],[167].
10.3.3. Extracorporeal Photochemotherapy (ECP)
In ECP, a patient’s leukocytes are collected, exposed to 8-methoxypsoralen, irradiated with
ultraviolet-A light and reinfused into the patient. The principle of ECP is to induce apoptosis
of leukocytes with ultraviolet-A radiation after their presentation by psoralens [170]. Early
apoptotic cells produce anti-inflammatory cytokines such as IL-10 and TGF-beta, which
stimulates their engulfment by macrophages and immature dendritic cells. The further
production of IL-10 and TGF-beta by these antigen presenting cells with subsequent down
regulation of proinflammatory cytokines such as TNF, IL-1 and IL-12 results in immunosu‐
pression and absence of co-stimulation of effector T cells [171]. A deficiency of apoptotic cell
clearance may contribute to the pathogenesis of autoimmune diseases including pemphigus
and therefore ECP may enhance clearance of autoreactive cells and the reduce formation of
pathogenic autoantibodies by B cells [172],[173]. Collectively, 9 patients, 8 with PV and 1 with
PF, originating from a small number of case studies and series, received ECP for refractory
disease in conjunction with their baseline immunosuprressive agents. [174]-[177]. In contrast
to the patients with PV, the lone patient with PF achieved only partial remission and long term
immunosuppression was unable to be weaned successfully [177]. ECP was well tolerated in
these patients with no adverse effects reported.
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10.4. Cholinergic agonists
Studies have suggested that acetylcholine and its receptors are involved in the acantholysis of
pemphigus. Approximately 85% of patients with pemphigus have antibodies against acetyl‐
choline receptors on keratinocytes [178]. Cholinergic antagonists mediate similar acantholytic
effects on keratinocytes as PV IgG [179]. Acantholytic antibodies can recognize the alpha-9
acetylcholine receptor [180] and pemphaxin [181], which can function as an acetylcholine
receptor. Finally, cholinergic agonists can prevent acantholysis in vivo [182] and reverse the
process in vitro [179].
Grando demonstrated a response in 3 of 6 patients with PV treated with pyridostigmine
bromide and conventional immunosuppression with 2 responders ultimately able to control
their disease with pyridostigmine bromide alone [183]. A recent double blind placebo con‐
trolled study comprising 3 PV patients showed a superior epithelialisation effect from 4%
pilocarpine gel compared with placebo [184]. The use of these agents in PF has not been
reported.
10.5. Peptide immunotherapy
Immunization  with  intravenous  desmoglein-3  peptides  was  developed  to  suppress
production of  anti-desmoglein-3  antibodies  through inactivation of  disease  specific  CD4
cells.  A phase  I  clinical  trial  in  PV patients  found no significant  change in  anti-desmo‐
glein-3  antibodies  following  administration  of  intravenous  desmoglein-3  peptides  [185].
Additional studies utilizing higher doses and longer treatment are in progress. It remains
to be determined whether peptide immunotherapy with desmoglein-1 peptides will have
a beneficial effect in PF.
10.5.1. Inhibitors of intracellular signalling and apoptosis
Studies performed by Berkowitz’s group have demonstrated the role of p38 mitogen-activated
protein kinase (p38MAPK) in the pathogenesis of pemphigus. Human keratinocytes treated
with PV IgG show a time and dose dependent increase in levels of p38MAPK and heat shock
protein 27 (HSP27) proteins involved in regulating cytoskeletal components such as keratin
intermediate filaments [186]. Inhibitors of MAPK signalling blocked phosphorylation of
HSP27 following PV IgG stimulation of human keratinocytes and importantly prevented
keratin filament retraction, an early change evident in acantholysis [186]. Inhibition of
p38MAPK in murine and cell culture models of pemphigus vulgaris also prevented blister
formation [187],[188]. The same group also recently demonstrated p38MAPK inhibition and
prevention of blister formation in a murine model of PF [189]. An open labelled uncontrolled
study is currently in progress to determine the safety and efficacy of the oral allosteric
p38MAPK inhibitor, KC706 (Kémia, Inc), in refractory PV.
Activation of protein kinase C (PKC) followed by plakoglobin dislocation and subsequent
dissociation of desmogleins from desmosomes also appear important in the pathogenesis
of  pemphigus [190]-[194].  Inhibitors  of  PKC and plakoglobin/c-myc proto-oncogene axis
have  been  shown  to  inhibit  PV  IgG  induced  blister  formation  in  the  neonatal  passive
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transfer  murine  model  of  pemphigus  vulgaris  [195].  It  has  been demonstrated that  p53
knockout  mice  are  protected  from  PV  IgG  induced  disease  [196].  Neonatal  mice  pre-
treated with p53 inhibitor pifithrin-alpha were resistant to both PV and PF IgG mediated
blister formation [197].
As shown by the studies of Waschke et al, PV autoantibodies directly block desmoglein-3
transinteraction  in  contrast  to  anti-desmoglein  antibodies  found  in  PF,  which  disrupt
desmoglein-1  transinteraction  via  cellular  signalling  events  rather  than  by  direct  inhibi‐
tion [198]-[200]. Hence targeting these signalling proteins in PF may provide a more specific
target of therapy as compared to immunosuppressive or biological agents. It remains to be
determined  whether  targeting  these  signalling  proteins  results  in  mediating  disease
remission in humans. Although they target specific areas of pemphigus pathogenesis, these
proteins mediate numerous cellular functions and hence the outcome of early safety studies
is eagerly awaited.
11. Elimination of triggering antigens
The elimination  or  avoidance  of  an  antigen  in  a  genetically  susceptible  individual  may
prevent  the  onset  of  disease  or  reduce  disease  activity.  Cessation  of  offending  medica‐
tions such as penicillamine or captopril results in remission of drug-induced PF [25],[201],
[202].  Similarly,  patients  with endemic pemphigus,  who relocate  from their  native rural
endemic environment to a more industrialized area experience clinical and immunologic
disease  regression  [203].  Hence,  the  clear  identification  of  a  triggering  environmental
antigen such as arthropod protein, microorganism or otherwise, will not only enhance our
understanding of disease pathogenesis but also significantly enhance therapies in endem‐
ic pemphigus and possibly non-endemic PF [5].
12. Conclusion
PV and PF are debilitating and potentially life-threatening conditions that are therefore
important to promptly recognize clinically and then confirm through their characteristic
features on histology and direct immunofluorescence. The detection of serum autoantibodies
by indirect immunofluorescence or ELISA does not obviate the need for a tissue diagnosis but
might be useful is assessing disease severity and activity.
Although, corticosteroids remain the cornerstone of therapy for pemphigus, the morbidity
associated with its use restricts its value as a long term treatment option. This is complicated
by the fact that steroid-sparing agents are also associated with serious adverse events and there
are only few randomized controlled trials demonstrating a beneficial response from the use of
these agents. This has been further compounded, until very recently, by the inconsistent
parameters of disease activity used in different studies. Azathioprine and mycophenolate
mofetil appear to be the most feasible first line adjunctive agents in terms of inducing and
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maintaining remission and having a comparatively favourable side effect profile. An enhanced
understanding of the pathogenesis of pemphigus has resulted in the implementation of a
number of novel agents. These therapies have also been mainly studies through case series
reports, are expensive and difficult to access in some centres, and are associated with a number
of deleterious side effects. Rituximab, has emerged as the therapy of choice in severe refractory
disease and is now being explored as a first line agent. We eagerly await further studies on the
effects and safety profiles of more specific agents, especially those targeting signalling
molecules involved in the pathogenesis of pemphigus.
We have formulated guidelines on the treatment of pemphigus as suggested by the current
level of evidence [204]. Corticosteroids remain the mainstay of treatment and should be
initiated at a dose of 0.5 mg /kg of oral prednisone per day and continued at this dose until
disease control is obtained. This is defined as the time at which new lesions cease to form and
existing lesions begin to heal and in responsive patients, this usually occurs within weeks. At
the end of the consolidation phase defined as the point in time where no new lesions have
occurred after 2 weeks and 80% of established lesions have healed, the corticosteroid dose is
tapered. Unless disease is mild we would recommend adding an adjuvant agent. Either
mycophenolate mofetil or azathioprine could be utilized at this stage. For severe or recalcitrant
disease rituximab is recommended given the current level of evidence. Other biologic agents,
extracorporeal therapies or cytotoxic agents can be considered if rituximab is unavailable or
contraindicated.
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